Compare Neurocrine Biosciences Inc (NBIX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Atlassian Corporation PLC — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Atlassian Corporation PLC trades at $176.91 (market cap $44.99B). The key difference: Atlassian Corporation PLC is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TEAM | |
|---|---|---|
Market Cap | $15.77B | $44.99B |
Sector | Health | Technology |
52-Week High | $185.50 | $194.68 |
52-Week Low | $123.10 | $57.15 |
Enterprise Value | $15.78B | $44.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Atlassian (TEAM) trades at $176.42, down 6.94% over 24 hours but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and a neutral RSI. Fundamentally, revenue growth is robust, climbing to $5.22B in 2025, though net income margins are negative. Recent earnings beats and AI integration into products like Rovo highlight operational strength, but high valuations and insider sales warrant caution.
Outlook is cautiously optimistic; analyst consensus is bullish with a $179.81 price target, driven by AI adoption and cloud expansion. Risks include premium valuation metrics, persistent net losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
